Caribou Biosciences, Inc. announced that it is exploring strategic alternatives to maximize stockholder value and is planning to discontinue further development activities for its two allogeneic CAR-T cell therapy programs: vispa-cel for the treatment of relapsed or refractory B cell non-Hodgkin lymphoma and Cb-011 for the treatment of relapsed or refractory multiple myeloma. In line with this decision, Caribou will implement workforce and cost reductions.

The decision marks a retreat from a pipeline the company originally positioned as pivotal trial-ready, reflecting broader difficulty across the allogeneic CAR-T sector in securing the capital needed to advance cell therapy programs toward commercialization.¹

Along with moving to discontinue programs, Caribou's board of directors has also approved initiating a process to evaluate strategic alternatives, including, but not limited to, a merger, acquisition, business combination, or other strategic transactions involving the company and its assets.¹

Why is Caribou discontinuing these programs?

"This is an extraordinarily difficult decision, particularly because it is in no way a reflection of our belief that vispa-cel and Cb-011 have the potential to benefit patients. Vispa-cel is pivotal trial-ready, with FDA alignment already reached on the Phase III clinical trial design. We believe both programs have demonstrated the potential for allogeneic CAR-T cell therapies to deliver deep and durable responses, while meaningfully expanding access for patients who urgently need treatment options," said Rachel Haurwitz, PhD, president and chief executive officer of Caribou.

"Unfortunately, despite the progress we've made, the current financing environment for allogeneic CAR-T cell therapies has made it increasingly challenging to secure the capital necessary to responsibly advance these programs. As a result, we've made the difficult decision to evaluate strategic alternatives and plan to discontinue further development of our allogeneic CAR-T cell therapy programs. We're deeply grateful to the patients and families who placed their trust in us, the physicians and site teams who partnered with us, and every member of the Caribou team whose skill and commitment brought these programs this far and advanced the field of cell therapy."

What are vispa-cel and Cb-011?

Vispacabtagene regedleucel, known as vispa-cel and formerly as Cb-010, is an allogeneic anti-CD19 CAR-T cell therapy evaluated in patients with relapsed or refractory B cell non-Hodgkin lymphoma.¹ To Caribou's knowledge, vispa-cel is the first allogeneic CAR-T cell therapy in the clinic with a PD-1 knockout, a genome-editing strategy designed to enhance CAR-T cell activity by limiting premature CAR-T cell exhaustion, and the first allogeneic CAR-T cell therapy to demonstrate safety, efficacy and durability on par with autologous CAR-T cell therapies.¹ FDA granted vispa-cel Regenerative Medicine Advanced Therapy, Fast Track and Orphan Drug designations for B cell non-Hodgkin lymphoma.

Cb-011 is an allogeneic anti-BCMA CAR-T cell therapy evaluated in patients with relapsed or refractory multiple myeloma.² To Caribou's knowledge, Cb-011 is the first allogeneic CAR-T cell therapy in the clinic engineered to enable activity through an immune cloaking strategy, using a B2M knockout and insertion of a B2M–HLA-E-peptide fusion protein to blunt immune-mediated rejection.² Clinical data from the Cb-011 Cammouflage Phase I trial demonstrated the potential for deep, durable responses in patients with relapsed or refractory multiple myeloma.² FDA granted Cb-011 Regenerative Medicine Advanced Therapy, Fast Track and Orphan Drug designations for relapsed or refractory multiple myeloma.

What happens next?

Wedbush Securities Inc. has been engaged as Caribou's exclusive financial advisor to assist in the strategic evaluation process. Caribou has currently not set a timeline for completion of the review and does not intend to provide further updates unless and until the board of directors has approved a course of action, the review process is concluded, or other disclosure is otherwise determined to be appropriate.¹

In conjunction with the announcement, Caribou plans to discontinue further clinical development activities and implement a substantial reduction in workforce, which is expected to be mostly complete in the fourth quarter of 2026.¹

As of June 30, 2026, Caribou had $113.8 million in cash, cash equivalents and marketable securities.

Sources

1. Caribou Biosciences to Evaluate Strategic Alternatives Caribou Biosciences October 6, 2026, https://investor.cariboubio.com/news-releases/news-release-details/caribou-biosciences-evaluate-strategic-alternatives
2. Caribou Biosciences Announces Positive Data from CaMMouflage Phase 1 Trial of CB-011 in Multiple Myeloma Caribou Biosciences November 3, 2025, https://investor.cariboubio.com/news-releases/news-release-details/caribou-biosciences-announces-positive-data-cammouflage-phase-1